Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday?

Humacyte, Inc. HUMA shares are trading higher on Friday. The company announced that the U.S. FDA has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV). HAV is used in urgent arterial repair following…#humacyteinchuma #usfda #priorityreview #humanacellularvessel #hav #fda #bla #lauraniklason #humacyte #v005phase23
Source: Reuters: Health - Category: Consumer Health News Source Type: news